JP2019507724A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507724A5
JP2019507724A5 JP2018535304A JP2018535304A JP2019507724A5 JP 2019507724 A5 JP2019507724 A5 JP 2019507724A5 JP 2018535304 A JP2018535304 A JP 2018535304A JP 2018535304 A JP2018535304 A JP 2018535304A JP 2019507724 A5 JP2019507724 A5 JP 2019507724A5
Authority
JP
Japan
Prior art keywords
dysplasia
prodrug
syndrome
pharmaceutically acceptable
cnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535304A
Other languages
English (en)
Japanese (ja)
Other versions
JP7051686B2 (ja
JP2019507724A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/050201 external-priority patent/WO2017118693A1/en
Publication of JP2019507724A publication Critical patent/JP2019507724A/ja
Publication of JP2019507724A5 publication Critical patent/JP2019507724A5/ja
Priority to JP2021031431A priority Critical patent/JP6951597B2/ja
Priority to JP2022054845A priority patent/JP7350123B2/ja
Application granted granted Critical
Publication of JP7051686B2 publication Critical patent/JP7051686B2/ja
Priority to JP2023147381A priority patent/JP7692454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535304A 2016-01-08 2017-01-05 大型のキャリアー部分を有するｃｎｐプロドラッグ Active JP7051686B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021031431A JP6951597B2 (ja) 2016-01-08 2021-03-01 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2022054845A JP7350123B2 (ja) 2016-01-08 2022-03-30 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2023147381A JP7692454B2 (ja) 2016-01-08 2023-09-12 大型のキャリアー部分を有するｃｎｐプロドラッグ

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16150624.1 2016-01-08
EP16150624 2016-01-08
EP16179286 2016-07-13
EP16179286.6 2016-07-13
EP16191458.5 2016-09-29
EP16191458 2016-09-29
PCT/EP2017/050201 WO2017118693A1 (en) 2016-01-08 2017-01-05 Cnp prodrugs with large carrier moieties

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021031431A Division JP6951597B2 (ja) 2016-01-08 2021-03-01 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2022054845A Division JP7350123B2 (ja) 2016-01-08 2022-03-30 大型のキャリアー部分を有するｃｎｐプロドラッグ

Publications (3)

Publication Number Publication Date
JP2019507724A JP2019507724A (ja) 2019-03-22
JP2019507724A5 true JP2019507724A5 (https=) 2019-12-19
JP7051686B2 JP7051686B2 (ja) 2022-04-11

Family

ID=57838356

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018535304A Active JP7051686B2 (ja) 2016-01-08 2017-01-05 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2021031431A Active JP6951597B2 (ja) 2016-01-08 2021-03-01 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2022054845A Active JP7350123B2 (ja) 2016-01-08 2022-03-30 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2023147381A Active JP7692454B2 (ja) 2016-01-08 2023-09-12 大型のキャリアー部分を有するｃｎｐプロドラッグ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021031431A Active JP6951597B2 (ja) 2016-01-08 2021-03-01 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2022054845A Active JP7350123B2 (ja) 2016-01-08 2022-03-30 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP2023147381A Active JP7692454B2 (ja) 2016-01-08 2023-09-12 大型のキャリアー部分を有するｃｎｐプロドラッグ

Country Status (8)

Country Link
US (6) US10835578B2 (https=)
EP (1) EP3400020A1 (https=)
JP (4) JP7051686B2 (https=)
AU (2) AU2017205268B2 (https=)
CA (1) CA3007976C (https=)
MX (1) MX2018008061A (https=)
WO (1) WO2017118693A1 (https=)
ZA (1) ZA201804414B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
EP3400021A1 (en) * 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
KR20190125310A (ko) 2017-03-10 2019-11-06 퀴아펙 파마슈티칼스 에이비 방출가능한 접합체
CN111918665B (zh) * 2018-03-28 2024-11-26 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
CA3112473A1 (en) 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
MX2021008708A (es) * 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
KR20230019889A (ko) 2020-06-03 2023-02-09 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 서열 및 이의 용도
JP2023530273A (ja) * 2020-06-12 2023-07-14 ファーマイン コーポレイション Ｃ型ナトリウム利尿ペプチド及び癌の処置におけるその方法
WO2023110758A1 (en) * 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
EP4529454A1 (en) 2022-05-23 2025-04-02 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
WO2000018422A1 (fr) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US8596542B2 (en) * 2002-06-04 2013-12-03 Hand Held Products, Inc. Apparatus operative for capture of image data
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
WO2008067127A2 (en) 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
CN101680287B (zh) * 2007-04-20 2013-12-18 国际壳牌研究有限公司 用于地下地层的加热系统和用于加热地下地层的方法
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
WO2009143412A2 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
PT2432489T (pt) * 2009-05-20 2016-12-07 Biomarin Pharm Inc Variantes do péptido natriurético de tipo c
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
MX349950B (es) 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
CA2843875C (en) 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
EP2853273A4 (en) 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd PROMOTER FOR BONE REPAIR
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20160118264A (ko) 2014-02-27 2016-10-11 다이이찌 산쿄 가부시키가이샤 스테로이드제 투여로 유발되는 성장 장해에 대한 의약
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
EP3242689A1 (en) * 2015-01-09 2017-11-15 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
HUE057083T2 (hu) 2015-12-08 2022-04-28 Biomarin Pharm Inc C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
US11564974B2 (en) * 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).

Similar Documents

Publication Publication Date Title
JP2019507724A5 (https=)
JP2019510735A5 (https=)
JP2019507725A5 (https=)
JP7692454B2 (ja) 大型のキャリアー部分を有するｃｎｐプロドラッグ
JP7714087B2 (ja) 増加したｎｅｐ安定性を有する徐放ｃｎｐ作動薬
JP7816947B2 (ja) 環部分にキャリア結合を有するｃｎｐプロドラッグ
KR102599552B1 (ko) Cnp 프로드럭
EP3400065B1 (en) Controlled-release cnp agonists with reduced side-effects
JP6685046B2 (ja) 長時間作用型アドレノメデュリン誘導体
CN103596584A (zh) 多取代的胰岛素
CA3064320A1 (en) Mic-1 compounds and uses thereof
CN105148289B (zh) 一种两亲性寡聚多肽药物结合物
US12415834B2 (en) GhR-binding peptide and composition comprising same
CN120641434A (zh) 人类运铁蛋白受体结合肽
HK1246666A1 (zh) Cnp前药
HK1246666B (en) Cnp prodrugs
HK1262548A1 (en) Cnp prodrugs with carrier attachment at the ring moiety